Pulmonary embolism due to a contraceptive vaginal ring (NuvaRing Õ ) I Krivokuca 1 and J-WJ Lammers 2
To the editor, Dear editor, The NuvaRing is a hormonal vaginal contraceptive ring (VCR), which is frequently prescribed.
We briefly describe here a young female, NuvaRing user with a pulmonary embolism to raise awareness of the occurrence of acute pulmonary embolism in young healthy women and to highlight what the Food and Drug Administration concluded that the vaginal contraceptive ring is associated with an increased risk of venous thromboembolism similar to that of oral contraceptives.
A 29-year-old female, user of a VCR NuvaRing, presented to our emergency department with an eightday history of dyspnea and chest pain. Usually she runs almost every day but since eight days she finds it difficult even to walk slowly due to dyspnea.
Her father was known with an antiphospholipid syndrome with pulmonary embolism but she was healthy and has no antiphospholipid syndrome or other clotting abnormalities.
Her respiratory rate was 24 breaths/min and her SpO 2 was 100% while breathing ambient air.
The patient's temperature was 36.8 and a C-reactive protein (CRP) was 16.
Her blood pressure was normal and her chest x-ray showed no abnormalities (Figure 1) .
The D-dimer level was 6 mg/l and a diagnosis of bilateral central pulmonary embolism was confirmed by computed tomography (Figure 2 ).
Discussion
The NuvaRing was introduced in the USA in 2001 as an alternative to combined oral contraception and is the first FDA-approved available combined vaginal contraception ring. 1 It contains the hormones estrogen and a progestin, which are slowly released and absorbed through the vaginal tissue. 
